January 16, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) posted Risk Management Plans (RMPs) for the rheumatoid arthritis treatment iguratimod on its website on January 8. The PMDA released RMPs for Eisai’s Careram Tablets 25 mg and Taisho Toyama Pharmaceutical’s Kolbet Tablets...read more